Review article: reflux and its consequences--the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010.

Abstract:

BACKGROUND:Gastro-oesophageal reflux disease (GERD) is one of the commonest diseases of Western populations, affecting 20 to 30% of adults. GERD is multifaceted and the classical oesophageal symptoms such as heartburn and regurgitation often overlap with atypical symptoms that impact upon the respiratory system and airways. This is referred to as extra-oesophageal reflux disease (EERD), or laryngopharyngeal reflux (LPR), which manifests as chronic cough, laryngitis, hoarseness, voice disorders and asthma. AIM:The 'Reflux and its consequences' conference was held in Hull in 2010 and brought together a multidisciplinary group of experts all with a common interest in the many manifestations of reflux disease to present recent research and clinical progress in GERD and EERD. In particular new techniques for diagnosing reflux were showcased at the conference. METHODS:Both clinical and non-clinical key opinion leaders were invited to write a review on key areas presented at the `Reflux and its consequences' conference for inclusion in this supplement. RESULTS AND CONCLUSION:Eleven chapters contained in this supplement reflected the sessions of the conference and included discussion of the nature of the refluxate (acid, pepsin, bile acids and non-acid reflux); mechanisms of tissue damage and protection in the oesophagus, laryngopharynx and airways. Clinical conditions with a reflux aetiology including asthma, chronic cough, airway disease, LPR, and paediatric EERD were reviewed. In addition methods for diagnosis of reflux disease and treatment strategies, especially with reference to non-acid reflux, were considered.

journal_name

Aliment Pharmacol Ther

authors

Pearson JP,Parikh S,Orlando RC,Johnston N,Allen J,Tinling SP,Johnston N,Belafsky P,Arevalo LF,Sharma N,Castell DO,Fox M,Harding SM,Morice AH,Watson MG,Shields MD,Bateman N,McCallion WA,van Wijk MP,Wenzl TG,Karkos

doi

10.1111/j.1365-2036.2011.04581.x

subject

Has Abstract

pub_date

2011-04-01 00:00:00

pages

1-71

eissn

0269-2813

issn

1365-2036

journal_volume

33 Suppl 1

pub_type

杂志文章,评审
  • Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study.

    abstract:BACKGROUND:Bovine colostrum is a rich source of nutrients, antibodies and growth factors. AIM:To examine the efficacy of colostrum enemas in the treatment of distal colitis using a randomized, double-blind, controlled protocol. METHODS:Fourteen patients (eight female), with a mean age of 45 years (range, 16-75 years)...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01354.x

    authors: Khan Z,Macdonald C,Wicks AC,Holt MP,Floyd D,Ghosh S,Wright NA,Playford RJ

    更新日期:2002-11-01 00:00:00

  • Systematic review: microscopic colitis.

    abstract:BACKGROUND:Collagenous and lymphocytic colitis are fairly common causes of chronic non-bloody diarrhoea, especially in elderly female. AIM:To present a systematic review of microscopic colitis. METHODS:A PubMed search using the MeSH terms microscopic colitis, collagenous colitis, lymphocytic colitis and chronic diarr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02913.x

    authors: Nyhlin N,Bohr J,Eriksson S,Tysk C

    更新日期:2006-06-01 00:00:00

  • Review article: metoclopramide and tardive dyskinesia.

    abstract:BACKGROUND:Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long-term or high-dose use of this medication because of the risk of developing tardive dyskinesia. A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04189.x

    authors: Rao AS,Camilleri M

    更新日期:2010-01-01 00:00:00

  • Serum gastrin levels during long-term omeprazole treatment.

    abstract::Serum gastrin was determined in 33 patients during treatment with the proton pump inhibitor omeprazole. After 4 weeks of therapy, gastrin levels increased to a median of 55 pg/ml compared to 15 pg/ml prior to omeprazole (P less than 0.001). There was a close correlation (r = 0.939; P less than 0.001) between pre-treat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1990.tb00457.x

    authors: Koop H,Klein M,Arnold R

    更新日期:1990-04-01 00:00:00

  • Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

    abstract:BACKGROUND:With the global efforts to eradicate hepatitis C virus (HCV), treatment during pregnancy is becoming a priority for research as this, and maternal cure should reduce vertical transmission. However, as information on the efficacy and safety of direct-acting antivirals (DAAs) in pregnancy is generally lacking,...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15476

    authors: Freriksen JJM,van Seyen M,Judd A,Gibb DM,Collins IJ,Greupink R,Russel FGM,Drenth JPH,Colbers A,Burger DM

    更新日期:2019-10-01 00:00:00

  • Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

    abstract:BACKGROUND:HS-10234 is a novel prodrug of tenofovir developed to increase anti-viral potency and to reduce systemic toxicities. AIMS:To evaluate the tolerability, pharmacokinetics and anti-viral efficacy of HS-10234 in patients with chronic hepatitis B (CHB) infection METHODS: Treatment-naïve subjects with non-cirrhot...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16196

    authors: Zhang H,Hu Y,Wu M,Liu J,Zhu X,Li X,Chen H,Li C,Liu C,Niu J,Ding Y

    更新日期:2021-01-01 00:00:00

  • Unanswered questions about Helicobacter pylori.

    abstract::There is general agreement that Helicobacter pylori eradication is indicated in all infected patients with duodenal ulcer disease and is probably indicated in all infected patients with gastric ulcer disease. However, translation of treatment recommendations into practice leads to some difficult clinical decisions. Th...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1995.tb00781.x

    authors: Walsh JH

    更新日期:1995-01-01 00:00:00

  • Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease.

    abstract:BACKGROUND:The detrimental effect of smoking on development and progression of Crohn's disease (CD) is generally accepted. AIM:To evaluate the awareness of smoking risks in a Belgian inflammatory bowel disease (IBD) population. METHODS:In the out-patient clinic of a tertiary referral centre, 625 consecutive patients ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13423

    authors: De Bie C,Ballet V,Hendriks N,Coenen S,Weyts E,Van Assche G,Vermeire S,Ferrante M

    更新日期:2015-12-01 00:00:00

  • Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

    abstract:AIM:To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study. METHODS:Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01292.x

    authors: Warrington S,Baisley K,Boyce M,Tejura B,Morocutti A,Miller N

    更新日期:2002-07-01 00:00:00

  • Review article: Helicobacter pylori and nonulcer dyspepsia.

    abstract::Although up to 50% of patients diagnosed with nonulcer dyspepsia (NUD) have Helicobacter pylori infection and underlying chronic gastritis, it remains controversial whether any causal relationship exists. The results of worldwide epidemiological studies have been unconvincing. No clear-cut link has been documented bet...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.0160s1058.x

    authors: Talley NJ,Quan C

    更新日期:2002-03-01 00:00:00

  • Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy.

    abstract:BACKGROUND:Helicobacter pylori infection is very common in India, as in other developing countries, but few data exist on the susceptibility of H. pylori to antimicrobial agents commonly used for eradication here. AIM:To determine the antimicrobial susceptibility of H. pylori strains from Kolkata, in eastern India. M...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2005.02533.x

    authors: Datta S,Chattopadhyay S,Patra R,De R,Ramamurthy T,Hembram J,Chowdhury A,Bhattacharya SK,Berg DE,Nair GB,Mukhopadhyay AK

    更新日期:2005-07-01 00:00:00

  • Symptom relief and duodenal ulcer healing with omeprazole or cimetidine. Opus (Omeprazole Peptic Ulcer Study) Research Group.

    abstract::In a double-blind parallel-group study, 98 patients with symptomatic duodenal ulcer received omeprazole 20 mg o.m. and 91 cimetidine 800 mg nocte for 2 or, if then not healed, 4 weeks. After 2 weeks the healing rates on an intention-to-treat basis were: for omeprazole 62% and for cimetidine 33% (P less than 0.001), an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00193.x

    authors: Crowe JP,Wilkinson SP,Bate CM,Willoughby CP,Peers EM,Richardson PD

    更新日期:1989-02-01 00:00:00

  • What the physician needs to know for correct management of gastro-oesophageal reflux disease and dyspepsia.

    abstract::Upper gastrointestinal symptoms are highly prevalent; usually those consulting have multiple symptoms, confounding management. Here, common clinically relevant management issues are considered based on the best available evidence. Regardless of the presenting symptoms, determine if there are any alarm features; these ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02043.x

    authors: Talley NJ

    更新日期:2004-07-01 00:00:00

  • Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.

    abstract:BACKGROUND:Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. AIMS:To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16016

    authors: Canbay A,Kachru N,Haas JS,Sowa JP,Meise D,Ozbay AB

    更新日期:2020-10-01 00:00:00

  • Efficacy of a standard United Kingdom oral rehydration solution (ORS) and a hypotonic ORS assessed by human intestinal perfusion.

    abstract::Human triple-lumen intestinal perfusion was used to compare water and solute absorption from the oral rehydration solution (ORS) most widely used in the United Kingdom and a new experimental hypotonic ORS (HYPO-ORS). HYPO-ORS (osmolality 210 mOsm/kg) promoted significantly greater water absorption than UK-ORS (7.03 +/...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1989.tb00249.x

    authors: Hunt JB,Elliott EJ,Farthing MJ

    更新日期:1989-12-01 00:00:00

  • Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.

    abstract:BACKGROUND:Therapeutic drug monitoring is a powerful strategy known to improve the clinical outcomes and to optimise the healthcare resources in the treatment of autoimmune diseases. Currently, most of the methods commercially available for the quantification of infliximab (IFX) are ELISA-based, with a turnaround time ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13757

    authors: Afonso J,Lopes S,Gonçalves R,Caldeira P,Lago P,Tavares de Sousa H,Ramos J,Gonçalves AR,Ministro P,Rosa I,Vieira AI,Dias CC,Magro F,Portuguese IBD Study Group (GEDII).

    更新日期:2016-10-01 00:00:00

  • Review article: visceral hypersensitivity.

    abstract::Visceral hypersensitivity is highly prevalent in all functional bowel disorders. Most also demonstrate wider patterns of somatic referral of intestinal pain or discomfort. This hypersensitivity may explain the symptoms as the sensitive gut can be more easily provoked by normal or abnormal motor events in the gut. Visc...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01447.x

    authors: Mertz H

    更新日期:2003-03-01 00:00:00

  • Viral nucleotide changes in asymptomatic hepatitis B carriers undergoing interferon treatment.

    abstract:BACKGROUND:Interferon might induce mutation in regions of hepatitis B virus DNA that encode for immunologic target of cytotoxic T lymphocytes. AIM:To investigate the short-term effect of steroid priming and interferon therapy on hepatitis B virus, we followed the nucleotide changes in the precore and core region of he...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1996.718898000.x

    authors: How W,Ng WC,Tan MF,Seet BL,Guan R

    更新日期:1996-04-01 00:00:00

  • The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

    abstract:BACKGROUND:It is not clear which dose of clarithromycin (500 mg b.d. or 250 mg b.d.) is more effective for Helicobacter pylori eradication in proton pump inhibitor-based triple therapies. METHODS:We undertook a meta-analysis of the effect of 7-day triple therapies consisting of a proton pump inhibitor (P), and clarith...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.1999.00530.x

    authors: Huang J,Hunt RH

    更新日期:1999-06-01 00:00:00

  • Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

    abstract:BACKGROUND:The guaiac faecal occult blood test (G-FOBT), HemoccultSENSA, is sensitive for significant neoplasms [colorectal cancer (CRC), advanced adenomatous polyps (AAP)], but faulted by non-specificity for human haemoglobin (Hb). Quantified, Hb- specific, immunochemical faecal occult blood tests (I-FOBT) are now use...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03898.x

    authors: Rozen P,Levi Z,Hazazi R,Waked A,Vilkin A,Maoz E,Birkenfeld S,Niv Y

    更新日期:2009-02-15 00:00:00

  • Review article: COVID-19 and liver disease-what we know on 1st May 2020.

    abstract:BACKGROUND:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), became a global threat to human health. Liver impairment has been frequently reported as a common manifestation, although its clinical significance is still unclear, particularly in pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15813

    authors: Garrido I,Liberal R,Macedo G

    更新日期:2020-07-01 00:00:00

  • Review article: impact of night-time reflux on lifestyle - unrecognized issues in reflux disease.

    abstract::Gastro-oesophageal reflux disease (GERD), manifesting with symptoms including heartburn and regurgitation, affects people during both daytime and nocturnal hours. Night-time GERD has been reported to have a greater impact on a patient's life than daytime GERD due to prolonged oesophageal acid exposure time per reflux ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02237.x

    authors: Shaker R,Brunton S,Elfant A,Golopol L,Ruoff G,Stanghellini V

    更新日期:2004-12-01 00:00:00

  • Oral and intestinal mucositis - causes and possible treatments.

    abstract::Chemotherapy and radiotherapy, whilst highly effective in the treatment of neoplasia, can also cause damage to healthy tissue. In particular, the alimentary tract may be badly affected. Severe inflammation, lesioning and ulceration can occur. Patients may experience intense pain, nausea and gastro-enteritis. They are ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01784.x

    authors: Duncan M,Grant G

    更新日期:2003-11-01 00:00:00

  • Clinical trial: oral zinc in hepatic encephalopathy.

    abstract:BACKGROUND:Hepatic encephalopathy has a negative effect on patient health-related quality of life (HRQOL). Zinc supplementation has been effective with regard to altered nitrogen metabolism. AIM:To investigate the effectiveness of oral zinc supplementation on hepatic encephalopathy and HRQOL. METHODS:Seventy-nine cir...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2010.04448.x

    authors: Takuma Y,Nouso K,Makino Y,Hayashi M,Takahashi H

    更新日期:2010-11-01 00:00:00

  • Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study.

    abstract:BACKGROUND:Interferon (IFN-alpha)-based regimens have been used with varying success in the treatment of chronic hepatitis C (CHC) for over two decades. The effect of such treatments on the natural course of CHC has been evaluated in small clinical trials with conflicting results. AIM:To investigate the natural course...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.03974.x

    authors: Manesis EK,Papatheodoridis GV,Touloumi G,Karafoulidou A,Ketikoglou J,Kitis GE,Antoniou A,Kanatakis S,Koutsounas SJ,Vafiadis I,HEPNET.Greece Cohort Study.

    更新日期:2009-05-15 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract:BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12912

    authors: Dawwas MF,Aithal GP

    更新日期:2014-10-01 00:00:00

  • Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

    abstract:BACKGROUND:Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. AIM:To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). METHODS:A postal questionnaire was sent to all French gastroenterologists among whom 4...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.04097.x

    authors: Oussalah A,Roblin X,Laharie D,Filippi J,Flamant M,Faure P,Phelip JM,Bigard MA,Peyrin-Biroulet L

    更新日期:2009-10-15 00:00:00

  • Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

    abstract:BACKGROUND:The presence of antibodies towards infliximab (ATI) is associated with lower infliximab (IFX) trough concentrations and loss of response. IFX treatment intensification is effective for restoring response in most, but not all patients with Crohn's disease (CD). AIM:To compare outcome, pharmacokinetics and im...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14452

    authors: Dreesen E,Van Stappen T,Ballet V,Peeters M,Compernolle G,Tops S,Van Steen K,Van Assche G,Ferrante M,Vermeire S,Gils A

    更新日期:2018-02-01 00:00:00

  • No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study.

    abstract:BACKGROUND:Dermatitis herpetiformis forms part of the same spectrum of gluten-sensitive disorders as coeliac disease yet may have different risks of morbidity and mortality. AIMS:To quantify the risks of fracture, malignancy and mortality in people with dermatitis herpetiformis compared with the general population. M...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03660.x

    authors: Lewis NR,Logan RF,Hubbard RB,West J

    更新日期:2008-06-01 00:00:00

  • Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children.

    abstract:BACKGROUND:There has been growing interest in the use of faecal microbiota transplantation (FMT) for the treatment of gastrointestinal and nongastrointestinal diseases. AIM:To review systematically the reported efficacy and safety of FMT in the management of gastrointestinal and nongastrointestinal disorders in adults...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12699

    authors: Sha S,Liang J,Chen M,Xu B,Liang C,Wei N,Wu K

    更新日期:2014-05-01 00:00:00